Moxifloxacin Hydrochloride + Dexamethasone is a combination medication used primarily for treating bacterial infections of the eye. Moxifloxacin is a fluoroquinolone antibiotic, and Dexamethasone is a corticosteroid. This combination treats infection while reducing inflammation, pain, and discomfort associated with ocular infections.
The combination of Moxifloxacin and Dexamethasone is used to:
| Brand Name | Moxifloxacin Hydrochloride + Dexamethasone |
|---|---|
| Type | |
| Weight | |
| Generic | Moxifloxacin Hydrochloride + Dexamethasone |
| Manufacturer | |
| Available in | English বাংলা |
Moxifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, which are essential for bacterial replication, transcription, and repair. By blocking these enzymes, Moxifloxacin halts bacterial growth and reproduction. Dexamethasone, on the other hand, is a corticosteroid that reduces inflammation by inhibiting the release of inflammatory mediators like cytokines and prostaglandins, thereby decreasing swelling and irritation.
Relief from inflammation and reduction in bacterial load may begin within a few days of starting treatment with Moxifloxacin + Dexamethasone. Improvement in symptoms is often seen within 48 hours, although complete resolution may take up to a week or more, depending on the severity of the infection.
Moxifloxacin has minimal systemic absorption when administered topically to the eye. Dexamethasone is also absorbed minimally when used in ophthalmic preparations, leading to limited systemic effects. However, both medications achieve effective local concentrations in the eye to combat infection and reduce inflammation.
Due to limited systemic absorption, Moxifloxacin and Dexamethasone used in ophthalmic solutions are predominantly cleared locally through tear drainage. Any small amounts that are systemically absorbed are metabolized in the liver and eliminated via the urine.
The typical dosage of Moxifloxacin Hydrochloride + Dexamethasone eye drops is 1 or 2 drops applied to the affected eye(s) every 4 to 6 hours. The duration of treatment may vary depending on the severity of the infection and the clinical response.
Moxifloxacin + Dexamethasone is administered as eye drops. Patients should wash their hands before applying the drops and avoid touching the tip of the dropper to any surface to prevent contamination. After instilling the drops, patients should close their eyes for a few minutes to allow the medication to spread evenly.
Common side effects include:
Toxicity from topical ophthalmic use of Moxifloxacin and Dexamethasone is rare due to limited systemic absorption. However, overuse of corticosteroids like Dexamethasone can lead to complications such as cataract formation, glaucoma, or secondary infections.
Use with caution in patients with a history of glaucoma or increased intraocular pressure, as corticosteroids can exacerbate these conditions. Prolonged use of corticosteroids can also lead to cataracts and delayed healing of eye wounds. The medication should not be used for viral or fungal infections of the eye.
Moxifloxacin + Dexamethasone may interact with:
Patients with glaucoma or a history of elevated intraocular pressure should be monitored closely while using Moxifloxacin + Dexamethasone due to the risk of worsening these conditions. Those with viral, fungal, or mycobacterial infections of the eye should not use corticosteroids.
Potential drug interactions include:
No significant food interactions are associated with the topical use of Moxifloxacin + Dexamethasone.
Moxifloxacin + Dexamethasone should be used during pregnancy only if the potential benefits justify the potential risk to the fetus. It is classified as Pregnancy Category C.
It is unknown whether Moxifloxacin or Dexamethasone are excreted in human breast milk following topical use. Caution should be exercised when administering the drug to breastfeeding women.
Due to the local administration of Moxifloxacin + Dexamethasone in the eye, overdose is unlikely. If accidental ingestion occurs, symptoms of overdose may include gastrointestinal upset or systemic corticosteroid effects. Treatment is supportive and symptomatic.
Moxifloxacin + Dexamethasone is contraindicated in patients with:
Patients should administer the prescribed number of drops into the affected eye(s) as directed by their healthcare provider. Contact lenses should be removed before application and can be reinserted 15 minutes after use. If multiple ophthalmic medications are used, they should be spaced at least 5 minutes apart.
Store Moxifloxacin + Dexamethasone eye drops at room temperature (between 20°C and 25°C) away from moisture and light. The bottle should be kept tightly closed when not in use.
Due to the topical nature of the drug's administration in the eye, the volume of distribution for Moxifloxacin + Dexamethasone is not well-defined for systemic use.
The half-life of Moxifloxacin when administered systemically is approximately 12 hours. The half-life of Dexamethasone varies based on the route of administration but is approximately 3 hours after systemic use. However, for ophthalmic use, systemic half-life is not a significant factor due to limited absorption.
Both Moxifloxacin and Dexamethasone are cleared primarily through hepatic metabolism. The minimal amount absorbed systemically after topical administration is eliminated through the urine.
See in details version Moxifloxacin Hydrochloride + Dexamethasone also Moxifloxacin Hydrochloride + Dexamethasone in bangla